Article Text

PDF
ASSA14-12-15 Efficacy and safety of direct thrombin inhibitor of bivalirudin during percutaneous coronary intervention therapy in AMI patients with Heparin-Induced Thrombocytopenia
  1. Z Xin,
  2. W Li,
  3. D Yu-Yang,
  4. H Ya-Ling
  1. Department of Cardiology, Institute of Cardiovascular Research of People’s Liberation Army, Shenyang Northern Hospital, Shenyang, Liaoning 110840, China

Abstract

Background To assess efficacy and safety of bivalirudin during PCI therapy in AMI patients with Heparin-Induced Thrombocytopenia(HIT).

Methods 488 patients were enrolled which comfirmed AMI by coronary angiography from July, 2012 to February, 2013, in which 10 patients were induced to come out Heparin-Induced Thrombocytopenia, 6 females, aged 48–79 years. The incidence of HIT patients was 2.0%. All patients were applied to bivalirudin (0.25 g, intravenous injection) during PCI. We summarised the characteristics of the patients, record incidence of in-hospital minor bleeding, major bleeding, platelet reduction and incidence of major adverse cardiac events (MACE) during hospitalisation and 1 month after discharge.

Results (1) There are no difference of primary endpoint (the blood platelet count of pre-PCI vs after PCI, (120.7 ± 43.2)109/L vs (137.2 ± 48.9)10 × 9/L, p > 0.05). (2) Successful rate of immediate post-procedure was 100%. (3) Safety: Hospitalisation and follow-up of 30 d, 10 patients had no life-threatening haemorrhage and MACE.

Conclusions bivalirudin, which can protect the activity of platelet, decrease mortality and mild haemorrhage, is feasible and safe for the patients with AMI during PCI therapy.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.